Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
L-asparaginase-induced apoptotic pathway in acute lymphoblastic leukemia (aLL)
FY 2020-21
Summary
Acute lymphoblastic leukemia (aLL), a malignancy characterized by rapid expansion of immature lymphocytes in the blood and bone marrow, is the most common paediatric cancer and the principal cause of cancer death among children. L-asparaginase (ASNase) is a central component of current combination chemotherapy for aLL but it comes with the risk of resistance. While newer targeted therapies have been developed, their effectiveness is enhanced when used in combination with chemotherapy, which remains to be the major treatment for aLL. Patients treated with ASNase-containing regimens show greater remission induction compared to those treated with ASNase-free regimens. However, the mechanisms by which ASNase causes aLL cell apoptosis remain elusive. The proposed project is primarily based on our lab's recent discovery of the ASNase resistance biomarker that serves as a critical element of the putative PAR2 signalling pathways stimulated by ASNase to induce aLL cell apoptosis. This is the very first attempt to elucidate the molecular mechanisms by which ASNase induces aLL cell apoptosis. Thus, our lab is in a unique and excellent position to address the above goal. My detailed and innovative combinatorial experimental approaches are expected to unambiguously define the involvement of the PAR2 signalling pathways in ASNase-induced aLL cell apoptosis. Results from my studies will, therefore, reveal new paths for advancing aLL research and for developing new strategies to treat aLL. Potential creation of modified forms of ASNase that cause enhanced PAR2 activation, and development of targeted therapy such as small molecular activators of PAR2 and activators/inhibitors of their downstream apoptotic mediators could prevent or stop the progression of aLL.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449659
Name
Kamran Hamza
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
L-asparaginase-induced apoptotic pathway in acute lymphoblastic leukemia (aLL)
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Lymphoblastic Leukemia; Apoptosis; Signaling
Abstract
Acute lymphoblastic leukemia (aLL), a malignancy characterized by rapid expansion of immature lymphocytes in the blood and bone marrow, is the most common paediatric cancer and the principal cause of cancer death among children. L-asparaginase (ASNase) is a central component of current combination chemotherapy for aLL but it comes with the risk of resistance. While newer targeted therapies have been developed, their effectiveness is enhanced when used in combination with chemotherapy, which remains to be the major treatment for aLL. Patients treated with ASNase-containing regimens show greater remission induction compared to those treated with ASNase-free regimens. However, the mechanisms by which ASNase causes aLL cell apoptosis remain elusive. The proposed project is primarily based on our lab's recent discovery of the ASNase resistance biomarker that serves as a critical element of the putative PAR2 signalling pathways stimulated by ASNase to induce aLL cell apoptosis. This is the very first attempt to elucidate the molecular mechanisms by which ASNase induces aLL cell apoptosis. Thus, our lab is in a unique and excellent position to address the above goal. My detailed and innovative combinatorial experimental approaches are expected to unambiguously define the involvement of the PAR2 signalling pathways in ASNase-induced aLL cell apoptosis. Results from my studies will, therefore, reveal new paths for advancing aLL research and for developing new strategies to treat aLL. Potential creation of modified forms of ASNase that cause enhanced PAR2 activation, and development of targeted therapy such as small molecular activators of PAR2 and activators/inhibitors of their downstream apoptotic mediators could prevent or stop the progression of aLL.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kamran, Hamza
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~